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Abstract 
This thesis focuses on the design, synthesis and utilization of fluorescent 
nucleobase analogues (FBAs). FBAs are an important class of compounds, 
used in the research of nucleic acids. The class of canonical FBAs, i.e. like 
the natural nucleobases, are of special interest as they can replace the 
natural nucleobases without significantly perturbing the overall structure 
and biological function of the nucleic acid. The overarching goal of the 
project was to establish a molecular binding interaction assay based on 
novel FBAs, to study ligand binding to oligonucleotides. 
This thesis starts with explaining the design rationale behind the class of 
quadra- and penta-cyclic adenine analogues, followed by the developed 
synthetic methods to such constructs. The developed synthetic scheme was 
used to prepare a library of over 50 novel multicyclic adenine analogues.  
One of the brightest molecules, pA, was incorporated and characterized 
inside DNA and was found to not perturb the overall structure of duplex 
DNA significantly. Moreover, pA was characterized as one of the brightest 
adenine analogues in DNA and RNA at the time of publishing. Follow-up 
studies revealed that pA can be detected via two-photon spectroscopy at a 
ratio of signal to background as low as five to one, meaning that our 
developed FBAs are approaching super resolution imaging applications. 
Another remarkable compound that was identified from the early 
screening study was 2CNqA, which just recently turned out to be the 
brightest FBA in DNA and RNA to date. The interbase FRET (Förster 
resonance energy transfer) properties were studied of 2CNqA in both 
DNA and RNA, and the probe accurately reports FRET of at least 1.5 turns 
of DNA, making it suitable to study changes over short DNA and RNA.  
The thesis is concluded with the synthesis, incorporation and 
characterization of the FRET pair tCO-tCnitro in RNA where they were used 
to monitor changes from A- to Z-form RNA. Furthermore, the FRET pair 
was then used to study the antibiotic class of aminoglycosides binding to 
RNA, faithfully reporting on their relative binding affinity of a pre-
microRNA construct. 
Keywords: Fluorescent nucleobase analogue, FRET, surface plasmon 
resonance, isothermal titration calorimetry, DNA, RNA, pre-microRNA, 
aminoglycoside, binding interaction. 
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1. General introduction and aims of the thesis 
During the past two decades a new class of regulators, microRNA (miR), 
have been identified to play a fundamental role in the regulation of cell 
development and function.1 Since the discovery of miRs in C. elegans in 
1993,2,3 more than 1900 genes coding for over 2600 miRs have been 
identified in humans.4 Their biogenesis is well characterized and the 
canonical pathway (Figure 1) can be briefly described as; genes coding for 
primary-miR (pri-miR, over 1 kb) are expressed and then processed inside 
the nucleus to precursor-miR (pre-miR, 70–90 nucleotides, nt), exported 
to the cytoplasm and further processed to mature miR (20–25 nt). The 
mature miR can in turn bind to and silence messenger RNA (mRNA), 
resulting in lowered protein expression. One third of the entire proteome 
is estimated to be regulated by these types of processes.5 
 
Figure 1. Simplified scheme of miR biogenesis and function. Adapted with 
permission.6 
As with all cellular processes, the biogenesis of miRs is not without fault 
and the dysregulation of miR levels has been associated with a number of 
disease states,7 including all forms of cancer.8,9 While miR are now well 
validated therapeutic targets, it is difficult to rationally design selective 
small molecule miR modulators, as structural motifs are shared amongst 
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several miRs.10 Antisense oligonucleotides (ASOs) that target miRs, have 
been explored therapeutically with miravirsen in early clinical trials.11 
Nevertheless, ASOs that target mRNA in general has been in development 
for over three decades and even as several concerns regarding stability, 
uptake and delivery has been solved, issues regarding toxicity still exists.12  
In the drug discovery process, assays are employed to discover lead 
molecules and to build structure-activity relationships (SAR) that can 
guide lead optimization and identify potential toxic or off-target effects.13 
With the identification of new therapeutic targets, the development of 
novel assays are also required. During the past decade we have seen the 
development of several new assays for the identification of small molecule 
miR binders, unfortunately with limited success.14,15 
The overall goal of my PhD project was to develop an in vitro assay 
suitable for monitoring small molecule binders to pre-miRNAs. This was 
to be achieved through the use of internally placed fluorescent RNA base 
analogues as Förster resonance energy transfer (FRET) pairs. In order to 
realize this goal, the following four milestones were defined: 
• Develop new fluorescent nucleobase analogues (FBAs) with 
desirable photophysical properties. 
 
• Synthesise phosphoramidite building blocks of FBAs amenable 
for solid-phase synthesis (SPS) of DNA and characterize the 
FBAs in an oligonucleotide context. 
 
• Develop the synthesis of phosphoramidite building blocks of 
FBAs for incorporation into RNA.  
 
• Develop a novel pre-miR binding interaction assay based on 
suitable RNA FRET FBA pairs. 
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2. Background 
The primary objective of this chapter is to introduce the theoretical 
background of this thesis and to provide a broad overview of nucleic acids, 
spectroscopy and binding interaction assays. 
2.1 Nucleic acids 
In eukaryotic life, DNA carries the genetic information required to 
produce the entire organism. DNA can be transcribed to RNA which acts 
as the transcript from which proteins are translated. Lately, RNA has 
turned out to be more complex than previously thought, being both 
functional and taking part in several other important regulatory 
pathways.16 
2.1.1 Structure and composition of oligonucleotides  
The monomeric units of DNA and RNA consists of a heterocyclic 
nucleobase linked via a C-N glycosidic bond to a pentose monosaccharide 
equipped with a 5'-OH phosphate group. If the pentose monosaccharide is 
ribose then the oligomer formed from linked monomers is defined as 
RNA, but if the pentose monosaccharide is deoxyribose then the oligomer 
is defined as DNA. Nucleosides are divided into two main categories: 
purines; constituted by adenosine (A) and guanosine (G) which can base-
pair to the pyrimidines; thymidine (T) or uracil (U) and cytidine (C) 
respectively (Figure 2a). Thymine occurs in DNA and uracil in RNA. 
 
Figure 2. a) The four nucleobases of DNA and uracil of RNA. R = deoxyribose 
or ribose. b) The nucleobase is constituted of either pyrimidines or purines; a 
nucleoside is the nucleobase with an attached (deoxy)ribose and a nucleotide 
furthermore carries from one, up to three 5'-OH phosphate groups. 
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If the monomeric nucleoside contains a 5'-OH phosphate group, it is 
termed nucleotide. Linked nucleotides via 5' to 3' phosphate bonds create 
oligonucleotides. DNA is commonly found in the B-form right-handed 
double helical structure and contains approximately 10 base pairs (bp) per 
turn of the double helix. While several other forms of double helical DNA 
exist,17,18 the A- and Z-form DNA are also considered biologically 
active.19–21  
The extra 2'-OH of ribonucleosides makes RNA more susceptible to 
hydrolysis than DNA, as the 2'-OH can attack the 3'-OH phosphate 
group.22 The extra hydroxyl on the pentose ring shifts the pentose ring 
conformation from a C2'-endo found in B-DNA to C3'-endo found in 
right-handed double helical A-RNA and A-DNA.22  
More noteworthy, RNA does not normally carry a complementary strand. 
This characteristic of RNA allows it to bend and self-base-pair in a unique 
fashion, creating a completely different set of secondary and tertiary 
structures, some of which are highlighted in Figure 3.23 In this sense, RNA 
is much more dynamic than DNA and a single type of RNA ensemble may 
sometimes be composed of several RNA conformations. 
 
Figure 3. Representation of various structural motifs in RNA. a) Stem or double 
helix. b) Hairpin loop. c) Bulge. d) Internal loop or mismatch. 
2.1.2 Targeting RNA with antisense oligonucleotides 
While the majority of commercial pharmaceuticals target proteins, other 
modalities are now being explored for pharmaceutical opportunities. Of 
the ~20,000 protein coding genes, approximately 3,000 are considered to 
be disease-related, where only ~700 of these have been therapeutically 
accessed.24,25 The main reason why more proteins have not been 
therapeutically accessed is partly due to the fact that they are difficult to 
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target, with some even labelled “undruggable”.24 However, in theory, it 
should be possible to target proteins deemed undruggable by interfering 
with their biogenesis. 
ASOs can interfere with the biogenesis of undruggable proteins by 
influencing the translation of RNA to proteins. ASOs binds to mRNA and 
inhibits the translation process to proteins.26 Although the development of 
oligonucleotide-based drugs has been ongoing for more than three 
decades, only eight drugs have entered the market as of mid 2019.27–29 The 
low number of drugs that have made it to the market are due to issues 
regarding poor in vivo biological activity, toxic off-target effects as well 
as poor absorption and distribution.30  
2.1.2 Targeting RNA with small molecules 
To date, the antibiotic linezolid, is the only synthetic small molecule drug 
on the market that specifically targets RNA (Linezolid, Figure 4).31 Other 
small RNA binding molecules discovered includes the antibiotic family 
of; aminoglycosides (Neomycin, Figure 4), macrolides (Erythromycin, 
Figure 4), tetracyclines (Tetracycline, Figure 4) and oxazolidinones 
(Pleuromutilin, Figure 4).32  
The majority of RNA binding compounds described to date are either 
intercalating, highly stacking/lipophilic and/or highly basic species 
resulting in positively charged compounds in physiological conditions. 
Such characteristics often leads to undesirable properties such as not being 
orally bioavailable or non-specific interactions between the small 
molecule and the RNA of interest.33 There currently seems to be a 
consensus in the field that RNA should be druggable using small 
molecules, as long as careful consideration is taken with regards to the 
choice of target, screening techniques to identify hits and identification of 
RNA motifs.34 
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Figure 4. The only designed small molecule targeting RNA (Linezolid), and four 
other discovered RNA binding small molecules, all of which are antibiotics. 
2.2 Spectroscopy 
Spectroscopy can be used in a multitude of experiments to measure 
various optical parameters. The focus in this thesis is mainly with the 
absorption and emission of light from small molecular labels/probes and 
oligonucleotides. 
2.2.1 Absorption and emission of light 
The absorption of light by molecules can be measured with a 
spectrophotometer. The instrument records how much of the incident light 
(𝐼𝑂) is passed through the sample (𝐼) at each wavelength. The absorption 
is calculated for each wavelength using equation 1. 
𝐴 = 𝑙𝑜𝑔 (
𝐼0
𝐼
)  [1] 
The absorption can be related to the concentration of the molecule under 
study using the Beer-Lambert law, where c is concentration (mol dm-3), ε 
is molar absorptivity (absorbance) and l is the path length (cm, Equation 
2).  
𝐴 = 𝑐 ∙ 𝜀 ∙ 𝑙  [2] 
Some molecules, when absorbing light, become excited from the ground 
state, S0, to the first excited state, S1, or higher states (Figure 5). In most 
cases the molecule relaxes to the ground state via non-radiative transitions 
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(rate determined by knr; Figure 5) such as internal conversion followed by 
vibrational relaxation. However, some molecules can relax to the S0 
ground state from the excited S1 state, via the emission of a photon (rate 
determined by kr; Figure 5). As some energy is lost to the surroundings 
mainly via vibrational relaxation in this process, the emitted light is always 
of longer wavelength than the absorbed light. 
 
Figure 5. Jablonski diagram showing the S0 ground state and the S1 excited state 
and main photophysical processes involved in absorption and emission. 
The fluorescent lifetime (𝜏) describes the average time a fluorophore 
spends in the excited states.  It is defined as the inverse sum of all 
processes that decreases the excited state, where kr is the rate at which the 
molecule relaxes to the ground state while emitting a photon and knr is the 
rate at which the molecules relaxes to the ground state without emitting a 
photon (Equation 3). The fluorescence lifetime can be measured via time-
correlated single photon counting (TCSPC). 
𝜏 =
1
𝑘𝑟+𝑘𝑛𝑟
   [3] 
The fluorescence quantum yield (Φ𝐹) is defined as the ratio between the 
number of photons a molecule emits and the number of photons it absorbs, 
which is equal to the ratio between the rate at which relaxation of the 
molecule relaxes via emission of a photon and the total amount of rates 
that depopulate the excited state (Equation 4). 
Φ𝐹 =
𝑝ℎ𝑜𝑡𝑜𝑛𝑠 𝑒𝑚𝑖𝑡𝑡𝑒𝑑
𝑝ℎ𝑜𝑡𝑜𝑛𝑠 𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑
=
𝑘𝑟
𝑘𝑟+𝑘𝑛𝑟
 [4] 
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2.2.2 Förster resonance energy transfer 
FRET is a process where molecules in an excited state can donate their 
energy to a proximal molecule in the ground state that acts as an acceptor. 
The following criteria must be met in order for FRET to occur: (I) the 
emission from the donor needs to overlap with the absorption band of the 
acceptor (Figure 6a); (II) the distance between the donor and acceptor 
needs to be close enough in space (Figure 6b-c); and (III) the orientation 
of the transition dipole moments (molecular antennae) of the donor and 
acceptor must not be perpendicular to each other (Figure 6d). 
 
Figure 6. Distance and orientation dependence of FRET between a donor and 
acceptor molecule. a) Spectral overlap between donor and acceptor. b) FRET 
occurs due to correct distance between donor and acceptor. c) FRET cannot occur 
due to too long distance between donor and acceptor. d) FRET does not occur due 
to incorrect orientation of donor and acceptor. 
The efficiency of the FRET process (FRETeff) can be measured by both 
steady-state fluorescence and TCSPC (Equation 5). 
FRET𝑒𝑓𝑓 = 1 −
𝐼𝐷𝐴
𝐼𝐷
= 1 −
𝜏𝐷𝐴
𝜏𝐷
  [5] 
Here D is donor, A is acceptor, DA refers to donor and acceptor present, 
I is intensity and 𝜏 is for average lifetime. 
 
9 
 
2.3 Binding interaction assays  
An assay can be defined as an investigative procedure for qualitatively or 
quantitatively measuring the presence, amount or functional activity of a 
target entity. This thesis focuses on assays that look at the molecular 
binding of small molecules to oligonucleotides, in particular that of 
RNA.35 
2.3.1 Label-free assays  
Label-free assays measure the interaction of molecules without the use of 
reporter tags such as radioisotopes or fluorescent dyes. A number of label-
free binding interaction assays exist such as monitoring small molecules 
interactions with proteins via nuclear magnetic resonance (NMR) 
techniques,36 affinity-chromatography coupled with mass detection,37 and 
various spectroscopy-based methods.38 Below follows a brief description 
of the assays used in this thesis, which will be described more thoroughly 
in section 3.4.1 and 3.4.2. 
2.3.1.1 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC), is a technique where a change in 
temperature is measured when a ligand is added to a sample of interest. 
ITC has found extensive use in the study of ligand-protein and ligand-
DNA interactions.39–41 Only a few studies have employed ITC for studying 
ligand-RNA interactions.42 Notable examples include tetracycline binding 
to riboswitches,43 aminoglycosides binding to 16 S ribosomal RNA,44 and 
aminoglycosides binding to the HIV-1 RNA dimerization initiation site.45 
2.3.1.2 Surface plasmon resonance 
Surface plasmon resonance (SPR) is a physical occurrence that happens 
when polarized light hits a thin metal film at the interface of media with 
different refractive indices and is the basis for several optical biosensors.46 
SPR applied to the measurement of small molecules interacting with 
macromolecules can be considered a label-free technique. SPR techniques 
have been used to study ligand-RNA interactions.47 Early studies focused 
on aminoglycosides binding to various RNA targets.48 SPR was also used 
to guide the design of bi-functional ligands for targeting the Rev response 
element, a highly structured 350 nt segment of HIV-1 mRNA.49 More 
recently SPR was used to validate hits generated from a fluorescent 
indicator displacement (FID) assay for ligands binding pre-miR-29a.50 
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2.3.2 Labelled assays 
Ideally, an assay should interfere as little as possible with the system under 
investigation. As previously mentioned, label-free assays are designed so 
that a physical parameter is measured, for example conductivity, mass or 
thermodynamic changes, they interfere minimally with the system 
investigated. However, in many cases label-free assays cannot be 
performed under biologically relevant conditions or lack the required 
throughput to allow screening of large libraries. A combination of 
orthogonal assay techniques is therefore required to validate both ligand-
target interaction and ensure biological relevance.13 In efforts to provide 
an overview of the assay which we set out to develop in my PhD project, 
the following sections describes a few different techniques. 
2.3.2.1 Microscale thermophoresis 
Microscale thermophoresis (MST), is a technique used to measure binding 
interactions in which it is required that the sample is fluorescently labelled. 
By either intrinsically labelling, or covalently attaching a fluorophore to a 
sample of interest, the mobility of the sample can be measured in a 
capillary tube with an induced temperature gradient (Figure 9).51 In 
comparison to SPR, MST requires no immobilization, uses a small sample 
size and can be used with cell lysate as the sample media, providing 
biologically relevant conditions.51 MST mainly provides binding constant 
data of ligand-complex interactions, but other parameters such as binding 
stoichiometry, thermodynamic parameters, such as enthalpy of the process 
(ΔH) and binding kinetics can be derived. The main drawback with MST 
is the limitation of which fluorescent reporter label can be used. Each 
instrument is built with a specific excitation laser that is combined with 
the infrared (IR) laser generating the temperature gradient, therefore 
making the change of the excitation wavelength rather laborious. The 
MST instruments are built either to excite tryptophan residues in proteins 
(excitation wavelength of 280 nm) or with an excitation source in the 
visible region ranging from 480 nm to 720 nm, therefore excluding those 
fluorescent dyes that exhibit an excitation maximum in between this range. 
MST has recently been used to study neomycin binding to the Rev 
responsive element of HIV-1 mRNA.52 
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Figure 7. The basics of a microscale thermophoresis (MST) experiment. 
2.3.2.2 Fluorescent indicator displacement 
FID assays work by first binding a fluorescent substance of medium 
affinity to the desired sample (Figure 10).53 Then the ligand under analysis 
is added. If the fluorescent substance is displaced by the ligand, change in 
emission is observed as the microenvironment around the probe, 
especially the polarity, changes. This signal change can be used to provide 
binding affinity information relative to the displaced probe. This type of 
system has been used in a high throughput format to study the interaction 
of small molecules with proteins,54 DNA,55 and RNA.56 
 
Figure 8. The principle of fluorescent indicator displacement (FID) assays. 
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2.3.2.3 Molecular beacon 
Molecular beacon (MB) fluorescence assay is a versatile assay where a 
short fluorescently labelled oligonucleotide (~25 nt) reports on the specific 
target through hybridization. The 5'- and 3'-ends of the oligonucleotide are 
labelled with a FRET pair, which, in an unbound state are in close 
proximity resulting is high FRETeff between the probes. As the 
oligonucleotide binds to its target through hybridization, the distance 
between the FRET pair increases, causing the FRETeff to be lower as a 
result.57 Recently, molecular beacons have been used to image RNA in 
live cells,58 and in screening the inhibition of miR maturation by small 
molecules.59 
2.3.3 Internucleobase labelled assays  
New modalities in drug discovery refers to the next generation of peptides, 
peptidomimetics, oligonucleotide-based molecules and novel hit finding 
technologies.60,61 One such example of a modality is the modulation of 
miR levels for therapeutic use. Even though great progress has been 
achieved in the development of miR modulators, small molecules that 
modulate miR are yet to reach clinical trials. This could be due to the fact 
that RNA itself is difficult to target,34 but possibly also due to the methods 
used to identify and evaluate the current small molecules as modulators of 
miR maturation. It is possible that since small molecule libraries are 
developed around proteins, no good RNA binding compounds are 
included.14 Indeed, the identified small molecule miR binders are all either 
highly lipophilic and/or highly charged molecules, and the few that are 
not, are potentially interfering with the maturation process by other means 
such as Dicer inhibition.15 There currently is a lack of understanding 
regarding which structural elements in RNA can be selectively targeted 
and by what type of compounds,62 something that interbase labelled assays 
could potentially shed light on. 
The concept of using FBAs to probe small molecule interactions to 
oligonucleotides has previously been exemplified with 2-aminopurine (2-
AP), which was used to probe small molecule binding to HIV-1 TAR 
RNA.63 Recently, a spin-labelled fluorescent probe was used in a structure 
guided fluorescence labelling approach, which revealed a two-step 
binding mechanism of neomycin to its RNA aptamer.64 The fluorescent 
probe, however, altered the binding affinity of neomycin significantly, 
thus better probes are required. 
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2.4 Fluorescent nucleobase analogues 
FBAs are fluorescent molecules that can be divided into two categories: 
(I) canonical, meaning that they are of similar size, shape and hydrogen 
bonding properties to mimic the native nucleobases; and (II) non-
canonical, meaning that no limit is put on the design of the molecule other 
than the function and photophysical properties of the probe.65 The central 
theme of this thesis is canonical FBAs and section 2.4.1 will briefly 
introduce these fluorescent entities. For a more comprehensive overview 
of both canonical and non-canonical FBAs see Wilhelmsson and Tor,66 
and the recent review articles from Tanpure et al.,67 and Xu et al.65 
2.4.1 Overview of canonical FBAs 
FBAs are powerful tools for studying structure and dynamics of nucleic 
acids as they can be placed close to the site of interest without perturbing 
the biological function of the nucleic acid. Depending on the intended 
application, FBAs, in general, should: 
• Retain the hydrogen bonding properties of the native nucleobase 
they are replacing. 
• Be small enough not to impact tertiary structure formation. 
• Have a high brightness for detection. 
• Be stable towards photodegradation. 
• Absorb light outside the absorption band of the natural 
nucleobases that is preferably significantly red-shifted. 
Fifty years ago, the foundation for fluorescent nucleobase analogues was 
laid when Stryer et al. published the fluorescence properties of three 
substances. One of which was 2-AP (Figure 9), considered the golden 
standard in the field of FBAs.68 Since then a number of FBAs have been 
developed and some of the most notable examples include; 8-vdA,69 the 
tricyclic cytosines tC and tCO,70,71 the pteridines (3-MI, 6-MI, 6MAP and 
DMAP),72,73 and the emissive isomorphic RNA alphabet (thA, thC, thG, and 
thU).74 
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Figure 9. Overview of fluorescent nucleobase analogues. R = (deoxy)ribose. 
FBAs have been used to study a number of processes where nucleic acids 
are involved. Recent examples include oxidative DNA alkylation repair,75 
the effect of mercury on DNA metabolism,76 DNA duplex formation,77 
and the use of FBAs for ultra-sensitive oligonucleotide detection.78 
The biggest challenges for the design and synthesis of FBAs includes the 
red shifting of the absorption for improved live cell imaging. Importantly 
also, making FBAs bright enough for single-molecule analyses and super-
resolution imaging. All while still keeping the FBA small enough to not 
adversely affect the biological properties of the studied system.65 
2.4.2 FRET FBA pairs 
A great number of FBAs have been developed and used in numerous 
applications. However, in order to gain valuable structural information, 
such as distance and orientation, more than one label is required. FRET 
FBA pairs (henceforth FRET pairs) are an example of a spectroscopic 
ruler.79 
Interbase FRET pairs are nucleoside pairs consisting of a fluorescent 
donor and a fluorescent acceptor. The donor absorbs incoming light, 
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becomes excited and can then, via FRET, donate its energy to a 
neighbouring acceptor molecule. The acceptor molecule either emits a 
photon or the energy is lost in a non-radiative pathway and the molecule 
returns to the ground state. 
Before the  commencement of this project, only one interbase FRET pair 
had been developed, namely the tCO-tCnitro as deoxyribonucleosides.80 
Since then, only one other interbase FRET pair has been developed by 
Sugiyama and co-workers in 2017, thdG-tC in DNA.81 During this project 
our group has developed several new interbase FRET pairs including 
qAN1-qAnitro in DNA,82 pA-qAnitro in DNA (Paper II), qAN4-qAnitro in 
DNA (manuscript in preparation), 2-cyano-qA (2CNqA)-qAnitro and 
2CNqA-tCnitro in RNA (Paper III), and tCO-tCnitro in RNA (Paper IV).  
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3. Methodology 
This chapter gives a brief overview of the main methods in the synthesis 
of nucleosides, the standard approach to synthesise oligonucleotides and 
the techniques used in this thesis for measuring the binding interaction of 
small molecules and oligonucleotides. 
3.1 Synthetic strategies 
Several different strategies to synthesise FBAs can be employed.  In this 
thesis, they are categorized into either divergent or convergent syntheses, 
depending on the linearity of the synthesis performed. A normal linear 
synthesis is done when the intermediates are moved towards the desired 
product one step at a time (Figure 10a).83 A convergent synthetic approach 
focuses on synthesizing fragments of approximately the same size and 
complexity that are connected towards the end of the synthetic scheme. 
The convergent approach is more common for the synthesis of larger 
amounts of material, as the number of reduced linear steps leads to an 
overall higher yield (Figure 10b). In contrast, a divergent synthetic 
strategy aims at generating a common intermediate from which several 
different products can be obtained, which allows for library synthesis 
around a common scaffold (Figure 10c).84 
 
Figure 10. Different synthetic strategies. a) Linear synthesis, carrying the same 
building block continuously forward. b) Convergent synthesis, connecting 
similarly sized fragments together. c) Divergent synthesis of several products via 
a common intermediate. 
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3.1.1 Convergent synthesis 
The convergent synthetic approach applied to the synthesis of nucleosides 
refers to a synthetic scheme where the nucleobase is fully constructed 
before performing a glycosylation with the desired sugar component. The 
convergent synthetic strategy was successfully applied in the synthesis of 
bicyclic thymine (bT, 7, Scheme 1).85 The desired sugar component (3) 
was first synthetically prepared starting from thymidine (1). The glycal 
was then coupled to the bicyclic core (6) via a Heck coupling. The 
convergent approach has been employed successfully by our group in the 
synthesis of the qAN1-qAnitro FRET pair.82 
 
Scheme 1. Synthesis of the FBA bT. Reagents and conditions: (a) TBDMS-Cl, 
imidazole, DMF, rt, overnight, 83%; (b) TBDPS-Cl, imidazole, DMF, 60 °C, 
overnight, 100%; (c) TFA:H2O 10:1, DCM, 0 °C, 4 h, 92%; (d) Ammonium 
sulphate, HMDS, 80 °C, then rt, TMS-Cl, reflux 4 h, 85%; (e) DMAP, pyridine, 
THF, Br2, BBr3, 85 °C, 2 h, 93%; (f) NaI, CuI, dioxane, trans-N,N'-
dimethylcyclohexane-1,2-diamine, 110 °C, 12 h, 54%; (g) Pd(OAc)2, AsPh3, 
tBuNH2, DMF 60 °C, 32 h, then TBAF, AcOH, 0 °C, 45 min, followed by 
ACN:AcOH 1:1, sodium triacetoxyborohydride, 0 °C, 1 h, 82%. 
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3.1.2 Divergent synthesis 
The most common approach to synthesise modified nucleobase 
phosphoramidite building blocks is to work in a combined linear and 
divergent fashion.86 The necessary synthetic handles are first installed on 
the desired nucleobase, such as chlorine or iodine for substitution and 
coupling reactions, respectively, which usually involves harsh conditions 
not suitable once the desired sugar component has been attached. These 
conditions may cause significant depurination. Glycosylation is then 
performed to achieve the (deoxy)ribonucleoside either via a substitution 
type reaction for deoxyribose or a Vorbrüggen reaction for ribose.87,88 The 
glycosylated base can then be used for further functionalization on the 
previously installed chemical handles such as; substitution, coupling 
reactions and click chemistry. A valuable feature with this approach is that 
most of the variability is introduced towards the end of the synthetic 
scheme, which simplifies FBA library generation. Small changes can have 
a dramatic impact on photophysical properties such as quantum yield of 
fluorescence.89 One successful example of applying the divergent strategy 
for generating a small FBA library was used by Dyrager et al. in the 
generation of C-8 triazole substituted adenines (Scheme 2).90 The alkyne 
(10) required for click chemistry was introduced via a Sonogashira 
coupling of (9) and nine different azides were installed on the C-8 position 
of adenine (12). 
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Scheme 2. Synthesis of C-8 substituted adenine via the divergent methodology. 
Reagents and conditions: (a) Br2/NaOAc buffer, 83%; (b) 
tetraisopropyldisiloxane dichloride, pyridine, 65%; (c) TMS/acetylene, 
Pd(PPh3)2Cl2, CuI, NEt3, THF, 50 °C, 50 min, 80%; (d) NH3 (aq. 25%)/EtOAc 
(1.5:1, v/v), rt, 14 h, 81%; (e) one of three protocols used: NaN3 in DCM/H2O, 
triflic anhydride, 0 °C, 2 h, then NaHCO3, benzylamine derivative, CuSO4-5H2O, 
rt, 30 min, MeOH, followed by 11, TBTA, L-ascorbic acid sodium salt, 60 °C, 
microwave (MW), 5 min; (f) TBAF (1 M in THF; 2 eq.), THF, rt, overnight, 99%. 
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3.2 Synthesis of nucleosides 
FBAs are typically either chemically functionalized natural nucleosides or 
constructed from the beginning where a novel heterocycle is investigated. 
Due to the large number of FBAs in the literature and the diversity of such 
compounds, few general synthetic approaches to synthesise FBAs exist.65, 
86 In this section, the most common synthetic methods to synthesise 
nucleosides via N-glycosylation are briefly described.91 
3.2.1 Fusion synthesis 
Fusion synthesis, also known as melt condensation, employs a nucleobase 
which reacts with a C1'-acetoxysugar. The reaction is normally performed 
under Lewis acidic conditions with high temperatures (>150 °C) and under 
vacuum, all while releasing volatile acetic acid (Scheme 3).92 The purine 
(14) was melted with the acetoxy-sugar (15), releasing AcOH yielding a 
bicyclic intermediate sugar that can accept a nucleophilic attack from the 
purine affording 16. 
 
Scheme 3. Early example of fusion synthesis to achieve N-glycosylation. 
Reagents and conditions: equimolar amounts of 14 and 15, 115 °C, 15 min. 
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The fusion procedure was used in the initial synthesis of the antiviral 
ribavirin (Scheme 4).93 Compound 15 was melted with the triazole (17) 
furnishing the isomers 18 and 19 in a 10:1 mixture. 
 
Scheme 4. Fusion synthesis to produce the antiviral ribavirin. Reagents and 
conditions: ~0.1 mol% bis(p-nitrophenyl)phosphate, 165 °C, vacuum, 20min, 
85% (10:1). 
3.2.2 Metal salt method 
The metal salt method was first used by Fischer et al. in the synthesis of 
the glucopyranoside (22, Scheme 5), where the silver salt of 2,6,8-
trichloropurine (20) was coupled with the bromo-sugar (21).94  
 
Scheme 5. Metal salt method used by Fischer et. al. to couple a purine with a 
pyranose. Reagents and conditions: Silver salt of 20 mixed with 21 in xylene. 
The metal salt method was later developed to employ mercury due to the 
increased reactivity and better solubility (Scheme 6).95 The mercury salt 
of 23 was coupled to the bromo-pentose (24) to furnish 25 in a modest 
yield (57%). 
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Scheme 6. Improved metal salt method utilizing mercury. Reagents and 
conditions: mercury salt of 23 mixed with 24 in xylene, reflux, 3 h, 57%. 
More recently, the toxic heavy metals previously used in the metal salt 
procedure have been replaced by sodium (Scheme 7). The sodium salt of 
2,6-dichloro-purine (26) was coupled to Hoffer’s α-chloro sugar (27) 
providing 28 in good yield (82%). Deprotection of the toluoyl groups was 
achieved by heating 28 with methanolic ammonia up to 150 °C for 20 h 
furnishing 29 in a good yield (71%). Where the previous methods often 
provided anomeric mixtures, positional isomers and low yields, the 
sodium salt method provided a cleaner reaction with higher yields, all 
while avoiding the use of mercury.87 
   
Scheme 7. Metal salt method employing sodium. Reagents and conditions: (a) 1 
eq. NaH, acetonitrile, rt, 30 min, then 1 eq. of 27, 50°C, 2 h, 82%. (b) NH3/MeOH, 
135-150 °C, 20h, 71%. 
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3.2.3 Vorbrüggen reaction 
The Vorbrüggen reaction (also known as the silyl-Hilbert-Johnson 
reaction) is based on the seminal work from Hilbert and Johnson, in which 
pyrimidines were reacted with halo-hexose sugars to form the N-
glycosidic bond.96,97 The Vorbrüggen reaction avoids the halo-sugars 
employed in the Hilbert-Johnson reaction in favour of -OAc or -OR sugars 
that are easier to synthesise, modify, purify and store. The method is mild 
and performed at room temperature with Friedel-Craft catalysts such as 
SnCl4, ZnCl2 or TMSOTf (Scheme 8). The benzoyl protected acetoxy-
sugar 30 was coupled to the pyrimidine 31 providing 32 in an excellent 
yield (95%). 
  
Scheme 8. Vorbrüggen reaction in the synthesis of nucleosides. Reagents and 
conditions: SnCl4, 1,2-dichloroethane, rt, 48h, 95%. 
3.3 Oligonucleotide chemistry 
Linked nucleotides form an oligonucleotide. This section describes the 
most widely used methodologies in chemical synthesis, purification and 
analysis of short oligonucleotides (<100 nt). The standard practices 
described do not apply for longer oligonucleotides (>100 nt) and will 
therefore not be considered. 
3.3.1 Oligonucleotide synthesis 
Early oligonucleotide chemistry connected two synthetic nucleotides 
together via H-phosphonate chemistry.98 The H-phosphonate chemistry 
was eventually adopted for solid-phase synthesis (SPS) of small 
oligonucleotides.99 In parallel to this, phosphodi- and tri-ester chemistries 
were developed which increased selectivity,100,101 that in turn opened up 
the use of more efficient coupling agents that dramatically reduced the 
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length of the synthesis and increased the yields significantly. In the 1970s, 
development of phosphite triester chemistry led Caruthers et. al. to pioneer 
the phosphoramidite chemistry that is being widely used today.102 Most 
commonly oligonucleotide synthesis is performed via SPS by fully 
automated machines, where each nucleotide, as a protected 
phosphoramidite building block, is incorporated by four distinct steps in a 
growing chain (Scheme 9).103 These steps consists of: 
1. Detritylation: the trityl group on the solid support is cleaved using 
TCA in DCM. 
2. Activation and coupling: the monomeric phosphoramidite 
building block are activated with 5-(benzylthio)-1H-tetrazole 
(BTT) and coupled to the nucleotide attached to the solid support. 
3. Capping: the unreacted material attached to the solid support is 
capped with a mixture of acetic anhydride and 1-methylimidazole 
to prevent accumulating n-1 species. 
4. Oxidation: the reactive phosphor(III) is oxidized to phosphor(V) 
by a mixture of I2, water and pyridine. 
Principally, the synthesis of DNA and RNA are identical. However, due 
to the 2'-OH in RNA, an additional protection group is required. Most 
commonly, TBDMS is used as it strikes the right balance between 
effectively removing the reactivity and potential 2'-OH to 3'-OH 
phosphate migration during synthesis and being small enough as not to 
add too much steric bulk. There is no defined maximum length of an RNA 
oligonucleotide synthesized with TBDMS protecting groups, although 
many commercial suppliers only provide oligonucleotides up to 45 nt. For 
longer RNA constructs other 2'-OH protection groups are recommended. 
Nonetheless, where the coupling step in DNA synthesis usually takes less 
than 30 seconds, it can take at least 10 times longer for RNA depending 
on a number of factors such as the choice of solid support, length of the 
oligonucleotide, or use of modified bases amongst others. 
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Scheme 9. Oligonucleotide synthesis cycle, R = nucleobase. 
3.3.2 Oligonucleotide workup, purification and analysis 
Upon synthetic completion of the oligonucleotide, some post-synthetic 
handling is required. The final 4,4-dimethoxytrityl (DMTr) protecting 
group is removed at the end of the synthesis using the same procedure as 
used during detritylation step of the oligonucleotide synthesis, i.e., while 
the oligonucleotide is still on the solid support (Scheme 10). However, the 
DMTr protection group can also be kept on the oligonucleotide as a 
hydrophobic handle to simplify reverse phase high performance liquid 
chromatography (RP-HPLC) purification for difficult separations.  
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Scheme 10. Detritylation of final 5'-OH trityl protection group. 
The 2-cyanoethyl (CE) phosphate protection groups are cleaved with a 
non-nucleophilic base such as DEA in acetonitrile via β-elimination 
(Scheme 11). This procedure is performed with the oligonucleotide still 
attached to the solid support and is done in a flow to rapidly remove any 
formed reactive acrylonitrile directly, which otherwise can undergo 
Michael addition to thymine or uracil. 
 
Scheme 11. Removal of the 2-cyanoethyl protection groups. 
Cleavage from the resin is achieved by using a mixture of concentrated 
aqueous ammonia and ethanol, which also removes the nucleobase 
protection groups (Scheme 12). 
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Scheme 12. Deprotection of the nucleobase protection groups and cleavage from 
the solid support. 
In the case of RNA, the 2'-OH protecting TBDMS groups needs to be 
cleaved, which is performed using a fluoride source, such as Et3N*3HF 
(Scheme 13). As RNA handling requires a fluoride source, additional steps 
of removing excess fluoride need to be added to the procedure. 
Precipitating the oligonucleotide with n-butanol followed by 
centrifugation and removing the supernatant is adequate. 
  
Scheme 13. Final deprotection step of RNA. 
The crude oligonucleotide is finally purified by RP-HPLC using a mobile 
phase consisting of acetonitrile and a slightly basic buffered solution. 
Short DNA sequences (<30nt) can be purified using readily available C8 
or C18 columns, however longer sequences (and especially RNA) sets 
high requirements on the stationary phase, where a small pore size is 
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critical to obtain high purity oligonucleotides. Ion-exchange 
chromatography can also be used, but this requires de-salting upon 
completion, whereas the buffer components in an RP-HPLC are usually 
volatile and depending on the desired counterion no extra salt swapping or 
desalting is required. Less practical, polyacrylamide gel electrophoresis 
can be employed to purify the oligonucleotide, generating high purity 
samples of the oligonucleotides, unfortunately in very small amounts. 
The final analysis of the synthesised oligonucleotide is to identify that the 
correct oligonucleotide has been synthesised, and to check the impurity 
profile. Usually, a detailed liquid chromatography–mass spectrometry 
(LC-MS) can provide the required data, but greater detail can be obtained 
by running a combined LC-time-of-flight-MS (LC-TOF-MS). 
3.4 Binding interaction measurements 
In this section two of the most common and readily available techniques 
for measuring small molecule binding interaction with an oligonucleotide 
are presented, which has been used in Paper V. The chapter ends with an 
explanation of how binding interaction of small molecules and 
oligonucleotides can be achieved by steady-state fluorescence and FRET. 
3.4.1 Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) is measured in a calorimeter with a 
sample and reference cell located in an adiabatic jacket (Figure 11a).104 
The raw data is displayed as a change in μcal/s against time and further 
processed to kcal/mol against the molar ratio of added ligand compared to 
sample (molar ratio). The data provided from analysis (Figure 11b) 
includes; binding affinity (Ka), enthalpy changes (ΔH) and stoichiometry 
of binding, usually referred to as the n value.  
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Figure 11. The basics of an isothermal titration calorimetry (ITC) experiment. 
ITC is a general technique and is often employed to measure small 
molecules binding to larger macromolecules.39 The two most common 
ITC machines are the full volume ITC (1000 uL cell volume) and the 
reduced volume ITC (200 uL cell volume). Standard conditions involve 
titrating a small amount of a ten times concentrated ligand to sample. 
Approximately twenty additions are performed, noting the enthalpic 
change in each instance over the course of one hour, giving ample time for 
equilibrium between most types of ligand and sample to form. The 
technique is laborious, requiring several reference runs to be performed. 
Collecting a complete binding interaction data set for one small molecule 
binding to one protein or oligonucleotide can take a full day. 
A complete set of data from ITC consists of four experiments: 
1. Sample of interest in cell to which the ligand of interest is titrated. 
2. Sample of interest in cell to which the buffer used is titrated. 
3. Buffer in cell to which the ligand of interest is titrated. 
4. Buffer in cell to which the buffer used is titrated. 
The results of experiments 2-4 are subtracted from experiment 1 which 
then shows the true enthalpic change contributed by adding the ligand of 
interest to the sample of interest. ITC is extremely sensitive and to obtain 
high-quality data the concentration and binding affinity of the sample and 
the ligand needs to match. Moreover, a careful selection of buffer 
conditions is required to avoid non-specific interactions between the 
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ligand and the buffer or the sample and the buffer. Another drawback of 
ITC is the relatively large amounts of sample and ligand that are required 
compared, for example, to techniques which employ fluorescence readout. 
3.4.2 Surface plasmon resonance 
Surface plasmon resonance (SPR) is measured on an SPR instrument. A 
large variety of instruments exists to suit the needs of the application, 
ranging from low-throughput systems where various parameters can be 
modified, to high-throughput systems, capable of screening 10,000 ligand 
interactions per day. The sample or the tested ligand is adhered to a metal 
surface (Figure 12). Normally, the biotin-streptavidin system is used, but 
covalent links have also been used.105  
 
Figure 12. The main phases of a surface plasmon resonance (SPR) experiment 
where a sample is adhered to a surface, the ligand of interest is bound and then 
dissociated, followed by a regeneration of the sample chip. Green marked area 
indicates data acquisition for binding affinity. 
The excess sample is washed away, followed by association of the ligand 
of interest. After a limited time, the ligand is allowed to dissociate which 
is followed by a sample regeneration by washing the chip. Data are 
recorded for several different concentrations of the sample being tested 
and are displayed in a histogram with time on the x-axis and response units 
(RU) on the y-axis. Marked in green (Figure 12) indicates steady-state and 
is where the response value is collected. An SPR experiment provides the 
binding constant (KD) and stoichiometry of binding, and detailed binding 
kinetics such as kon and koff. 
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3.4.3 Steady-state emission spectroscopy  
In steady-state emission spectroscopy the emission of photons from a 
molecule is measured using a spectrofluorometer. The sample is typically 
continuously illuminated by a white light lamp where one wavelength at 
the time is monitored and the emission of the sample is captured in a 
detector. Several different cuvettes exist, and the most common ones are 
standard 1.5-3 mL cuvettes, but sizes range down to 60 uL reduced volume 
cuvettes for precious samples. When observing biomolecules such as 
proteins and oligonucleotides one needs to be aware of any effect of 
surface adhesion that the plastic pipette tips and quartz surfaces might 
have on the sample of interest.106 
The intensity of emitted light that is measured can be compared to that of 
a known compound providing the fluorescence quantum yield. By 
observing the change in quantum yield for a sample labelled only with a 
FRET donor compared to a sample with a paired FRET acceptor, we can 
determine whether the change in quantum yield originates from changes 
in the local microenvironment of the FRET donor, or if the change 
originates from a difference in distance or orientation of the FRET pair. If 
we instead use a FRET pair where the donor and acceptor are virtually 
unresponsive to changes in the local microenvironment, such as tCO-
tCnitro,80 we would know that any change in the fluorescence quantum yield 
comes from a change in either relative distance or orientation between the 
probes directly. 
To test if a ligand interacts with an oligonucleotide, the following 
experiment may be performed. The fluorescently labelled oligonucleotide 
sample is dissolved in the desired buffer and added to a cuvette. An 
emission spectrum is recorded and then the ligand of interest is added 
where upon a new emission spectrum is recorded. Any change in measured 
emission, accounting for dilution, originates from a binding event of the 
ligand of interest to the oligonucleotide. 
3.4.4 Time-resolved emission spectroscopy 
Time-resolved fluorescence lifetimes can be measured using a time-
correlated single photon counter (TCSPC) setup. The sample is placed in 
a cuvette in which a pulsed laser can excite the sample. Each pulse excites 
a part of the sample and the aim is to measure the decay of the excited state 
as a function of time. Because emission is a random process, some 
molecules will emit a photon after a short period of time, where others will 
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emit after a longer period. For most small molecules, the fluorescence 
lifetimes are in the nanosecond regime and the special electronic setup 
makes it possible to measure the time between the excitation of the sample 
and the detection of a photon in the detector. 
Both steady-state and time-resolved emission spectroscopy can be used to 
determine quantum yield, and, thereby, also FRETeff. However, time-
resolved emission spectroscopy is not concentration dependent and can 
provide additional insight into subtle changes in quantum yield where for 
instance a ligand is titrated into the sample, reducing the sample 
concentration. 
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4. Original work 
This chapter summarises the work presented in the five papers that 
comprise this thesis. The first section explains the design and synthetic 
process undertaken to create fluorescent adenine analogues (Paper I), 
followed by the synthesis and incorporation of adenine FBAs into DNA 
(Paper II). The synthesis chapter is concluded by explaining the synthesis 
and incorporation of FBAs into RNA (Papers III–IV). The final section 
demonstrates how our developed probes can be used to study the binding 
interaction of RNA and small molecules (Paper V). 
4.1 Design and synthesis of new FBAs 
This chapter intends to present the key transformations and synthetic steps 
that yielded novel fluorescent nucleobase analogues (Papers I–IV). 
Figure 13 illustrates the A and C analogues that have been developed. 
 
Figure 13. Structures of developed DNA and RNA phosphoramidites. For X = N, 
Y = H, qAN1, for X = H, Y = N, qAN4. R = deoxyribose or ribose. 
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4.1.1 Design of non-perturbing FBAs 
The development of bright non-perturbing FBAs remains a challenge. 
Small modifications to the native nucleobases can introduce 
fluorescence.68,107 More dramatic changes, such as extending the 
conjugation via aromatic ring-fusion or introducing fluorescent labels such 
as pyrene conjugated to the nucleobase, can lead to greater brightness 
(molar absorptivity multiplied by quantum yield of fluorescence, εΦF) but 
is limited by issues such as interaction with the tertiary structure of the 
oligonucleotide.108,109 Thus, a careful consideration of the geometrical 
constraints is required before attempting to construct a novel, bright, and 
most importantly, non-perturbing FBA. The adenine scaffold offers 
several sites for modifications: C2, C8, the C6 exocyclic amino 
functionality and the N7 to C7 substitution leading to 7-deazaadenines.86 
In general, the modifications encountered by the hydrogen bonding 
surface such as C2 or C6 exocyclic amino substitutions are problematic as 
they can potentially interfere with the hydrogen-bonding properties of the 
nucleobase. Substitutions on the C8 have proven to destabilise the double 
helix by pushing the glycosidic bond from anti to syn.110–112 However, 
switching N7 to C7 and placing substitutions on the C7 position can be 
tolerated.113 
To date, there are no accurate means to predict the fluorescent properties 
of small molecules and thus correctly guide their synthesis. In general, 
conjugated aromatic molecules increase molar absorptivity, and the 
introduction of heteroatoms red-shift the molecule’s absorption. However, 
it is unclear as to how the quantum yield is affected by such modifications. 
In some cases, calculating the S0–S1 oscillator strength can be indicative 
of the relative quantum yield within a set of compounds.89 Furthermore, 
the incorporation of FBAs into oligonucleotides generally quenches the 
emission, and the mechanisms are not completely characterised, further 
increasing the complexity of the FBA design.82 To generate a building 
block required for DNA or RNA, SPS typically requires great effort in 
terms of protecting reactive fragments, and the entire synthesis of such a 
compound can easily become a tedious multi-step process. Therefore, it is 
necessary to know that the FBA that is being made will be valuable in 
terms of photophysical properties, and our approach has been to synthesise 
only the heterocyclic moiety of the FBA that is responsible for fluorescent 
properties. By shortening the number of steps and simplifying the 
previously developed chemistries we could synthesise focused libraries of 
advanced heterocyclic scaffolds. 
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4.1.2 Fluorescent multicyclic adenine analogues 
Our starting point was the quadracyclic adenine (qA) that was developed 
previously by our group.114 We chose this scaffold, as we knew it was an 
excellent adenine analogue in terms of size, shape, and base pairing 
properties. Unfortunately, the photophysical properties were not great, 
with a modest quantum yield of 0.07 as a monomer and almost completely 
quenched with a quantum yield of 0.003 on average in double-stranded 
DNA (dsDNA).114 Upon examining the structure, it was apparent that we 
could introduce modest modifications to ideally increase quantum yield as 
well as red-shift the absorption. However, by observing the linear 11-step 
synthetic scheme of qA with a total yield of 1.5%, it was apparent that 
synthesising several modified qA derivatives would be extremely 
laborious. Ideally, we would only synthesise the heterocyclic moiety as a 
preliminary-FBA (pre-FBA). The reasoning was that if the substituent on 
the N-9 of the purine scaffold was non-aromatic and non-conjugated to the 
aromatic system, it would adequately resemble the deoxyribose 
component to indicate whether the synthesised pre-FBA was a good 
candidate for DNA phosphoramidite synthesis. 
By performing a retrosynthetic analysis of the qA scaffold we found two 
short and similar routes leading to commercially available reagents. By 
first disconnecting the secondary amine between the top and the bottom 
aromatic rings, we ended up with the possibility of performing an 
intramolecular cyclisation by substituting the chloride for an exocyclic 
amino group (34, route A, Scheme 14). The next disconnection was made 
at the C-7 deaza-position of adenine, furnishing a 6-chloro-7-iodo-
deazapurine scaffold (36), which is commercially available lacking 
substitutions on N9 and an ortho-boronpinacolester-aniline species (37). 
In the second route (route B, Scheme 14), the first disconnection is made 
at the C-C bond joining the top and bottom aromatic rings, assumed to be 
possible to form from an intramolecular cross-coupling reaction such as 
Suzuki-Miyaura cross-coupling (35). The second disconnection 
performed at the secondary amine generates the same starting materials as 
for route A. 
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Scheme 14. Retrosynthetic analysis of 33. R1 = protecting group or alkyl chain. 
R2 = freely selectable substituent. 
We opted for route A and the synthesis commenced from commercially 
available 6-chloro-7-iodo-deazapurine (38, Scheme 15, Paper I). In order 
to not impact the photophysical properties, we determined that an ethyl 
group instead of the ribose on the N9 position would be adequate. The 
ethylated product (39) was obtained in 90% yield under anhydrous 
conditions with a slight excess of ethyl iodide and caesium carbonate in 
DMF and without the need for column chromatography. Miyaura 
borylation of 39 with pinacolborane and an excess of triethylamine in 
dioxane provided 40 in 86% yield after flash chromatography. A catalyst 
screening was carried out resulting in the conditions presented in Scheme 
15 (for details see Paper I). A slight excess in equivalents of the ortho-
iodo-anilines was coupled to 40 via a Suzuki-Miyaura cross-coupling 
utilising PdCl2(PPh3)4 as the catalyst in good yield.115 Finally, the 
cyclisation was performed by treating 41–44 with chlorotrimethylsilane 
(TMS-Cl) to increase the exocyclic nitrogen’s nucleophilicity,116 followed 
by the addition of excess lithium bis(trimethylsilyl)amide (LiHMDS) to 
yield 45–48 in moderate to good yield (55-71%). 
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Scheme 15. Synthesis of ethylated qAN1-4 FBAs. Compounds 41 and 45, W = 
N and X, Y, Z = CH. Compounds 42 and 46, X = N and W, Y, Z = CH. 
Compounds 43 and 47, Y = N and X, W, Z = CH. Compounds 44 and 48, Z = N, 
W, X, Y = CH.  Reagents and reaction conditions: (a) EtI (1.2 eq.), Cs2CO3 (1.2 
eq.), DMF, rt, 4 h, 90%. (b) HBpin (1.1 eq.), Pd(PPh3)4 (3 mol%), Et3N (10 eq.), 
dioxane, 80 °C, 24 h, 86%. (c) Aniline (1.1 eq.), PdCl2(PPh3)4 (3 mol%), K3PO4 
(2.5 eq.), MeCN-H2O 1:1, 80 °C, 2 h, 56-79%. (d) TMS-Cl (1.05 eq.), rt, 30 min, 
ii) LiHMDS (2.5 eq.), 100 °C, MW, 3 h, 55-71%. 
Using this chemistry, we synthesised 12 additional qA-derivatives.89 
However, to how incorporation into DNA and/or RNA would affect 
photophysical properties was yet to be observed. In parallel to developing 
the first probes for DNA SPS, over 20 pre-FBAs were synthesised in the 
group, and their photophysical data were evaluated (49–60, data not 
published, Figure 14), However, only the most interesting species were 
progressed into phosphoramidites for oligonucleotide incorporation. 
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Figure 14. Various synthesised aromatic heterocycles (49–60), data not 
published. 
4.1.3 Synthesis of DNA phosphoramidites  
Derived from the photophysical characterisations performed in Paper I, 
the first target FBA for incorporation was qAN1. The synthesis and 
incorporation of the fluorescent probe, FRET donor qAN1, and the FRET 
acceptor/quencher qAnitro was achieved, thereby constituting the first 
adenine–adenine interbase FRET-pair.82 During the development of the 
synthetic scheme for the qAN1 FBA, we continued to synthesise several 
other fluorescent adenine pre-FBAs.89 The size-expanded quadracyclic 
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adenine scaffold, pentacyclic adenine (pA, Paper II, data not published 
for the pre-FBA) and the 2CNqA compound89 were of particular interest. 
Thus, we set out to establish a viable synthetic route built on a convergent 
design strategy, utilising a late-stage glycosylation. The idea was that the 
synthesised heterocyclic nucleobase scaffold can be functionalised freely 
in the N9 position, employing any glycosylation chemistry. DNA 
phosphoramidite of 2CNqA was made identically as the route of pA 
shown below. 
The multi-gram synthesis started from commercially available 6-chloro-
7-deaza-7-iodo-purine (38), which was protected in a two-step procedure 
using formaldehyde under basic conditions followed by tert-
butyldimethylsilyl trifluoromethanesulfonate (TBDMSOTf) in pyridine to 
yield the N-9 protected deaza-purine in 86% yield after filtration (61, 
Scheme  16).117 The common intermediate used for both pA and 2CNqA 
was prepared through the borylation of 61, under previously developed 
conditions (Paper I) in high yield (91%). This two-step protocol was used 
to prepare batches of >25 g of 62 (data not published). 
 
Scheme 16. Synthesis of common intermediate used to prepare various quadra- 
and penta-cyclic DNA phosphoramidites. Reagents and reaction conditions: (a) i) 
HCHO (2 eq.), NaOH (0.1 eq.), MeCN, 50 °C, 1 h. ii) TBDMS-OTf (1.2 eq.), 
pyridine, 0 °C, 30 min, 86%. (b) HBpin (1.2 eq.), Pd(PPh3)4 (2.5 mol%), Et3N 
(1.5 eq.), dioxane, 90 °C, 4.5 h, 91%. 
Utilising the previously mentioned Suzuki-Miyaura cross-coupling 
(Paper I),82,89 the reaction between 62 and 3-amino-2-iodo-naphtalene 
(63) with PdCl2(PPh3)4 furnished 64 in good yield (71%, Scheme 17). 
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Scheme 17. Synthesis of 64 en route to pA DNA phosphoramidite. Reagents and 
reaction conditions: 3-amino-2-iodo-naphtalene (1 eq.), PdCl2(PPh3)4 (4 mol%), 
K2CO3 (2.5 eq.), MeCN-H2O 19:1, 80 °C, 1.5 h, 71%. 
The synthetic route was continued with employing a two-step protocol to 
cyclise the scaffold (Scheme 18). The exocyclic amino group of 64 was 
activated for nucleophilic aromatic substitution by being reacted with 
acetyl chloride under basic conditions in DCM to furnish 65. Then, the 
reaction mixture was evaporated until dry, followed by re-dissolving in 
THF to which LiHMDS in excess was added and the reaction mixture was 
heated in the microwave. This yielded the cyclised pentacyclic adenine 
scaffold (66) in good yield (73%, Scheme 18). We needed to use different 
activation procedures for the exocyclic amine than for the ethylated qAN1-
4 synthesis (Scheme 15). As we scaled the reaction up from the synthesis 
of the pre-FBAs (Paper I),89 the activation by silylation was difficult to 
control, with doubly silylated material generated as the main by-product. 
 
Scheme 18. Synthesis of the pentacyclic scaffold 66. Reagents and reaction 
conditions: (a) AcCl (1.15 eq.), pyridine (1.25 eq.), DCM, rt, 1 h. (b) LiHMDS 
(1.8 eq.), THF, 100 °C, MW, 30 min, 73%. 
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To prepare the nucleobase for glycosylation, a protection group was 
required at the N6 position and the N9 was required to be unprotected. 
First, the tert-butyloxycarbonyl (Boc) protection of 66 was achieved using 
Boc anhydride in excess with 4-dimethylaminopyridine (DMAP) in THF 
with a good yield (80%) of 67 (Scheme 19). Then, tert-
butyldimethylsilyloxymethyl (TBDMSOM) removal was performed using 
tetra-butylammonium fluoride (TBAF) and ethylenediamine in high yield 
(92%) of 68.  
 
Scheme 19. Synthesis of 68 ready for N-glycosylation. Reagents and reaction 
conditions: (a) Boc2O (2.2 eq.), DMAP (2.5 eq.), THF, rt, 24 h, 80%. (b) TBAF 
(1 eq.), ethylenediamine (2 eq.), THF, 0 °C, 15 min, 92%. 
Glycosylation was then performed using the metal-salt method (Scheme 
20),87 in which sodium hydride was pre-stirred with the nucleobase (68), 
thus achieving the full deprotonation of the N9 and keeping the sodium as 
a counter-ion. Hoffer’s α-chloro-sugar (27),118 was then added in a slight 
excess which furnished 69 in a modest yield (57%). 
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Scheme 20. Synthesis of protected pA nucleoside 69 by the metal salt method. 
Reagents and reaction conditions: i) NaH (1.35 eq.), MeCN, 0 °C, 3 h. ii) Hoffer's 
α-chloro-sugar (1.2 eq.), rt, 2 h, 57%. 
Previously, for deprotection during the synthesis of qA, a low-yielding 
two-step deprotection approach was employed, in which the Boc group 
was first cleaved under acidic conditions, and then the toluoyl groups were 
cleaved under basic conditions.114 Increasing the basicity of the sodium 
methoxide by changing the solvent from methanol to acetonitrile, we 
achieved global deprotection without the need for chromatographical 
purification, thus turning the low yield into quantitative (Scheme 21).  
 
Scheme 21. Synthesis of the unprotected pA nucleoside 70. Reagents and reaction 
conditions: NaOMe (6 eq.), MeCN, 50 °C, 20 min, 99%. 
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The completion of the DNA phosphoramidite for SPS (72, Scheme 22) 
was achieved by DMTr-protection of the primary alcohol of 70 with a 
modest yield (59%), followed by the phosphitylation treatment of 71 with 
chloro-(2-cyanoethoxy)diisopropylaminophosphine (CEP-Cl) providing 
72 in high yield (88%). 
 
Scheme 22. Synthesis of pA DNA phosphoramidite that is ready for SPS. 
Reagents and reaction conditions: (a) DMTr-Cl (1.3 eq.), pyridine, rt, 1.5 h, 59%. 
(b) CEP-Cl (2 eq.), N-methylmorpholine (4 eq.), DCM, rt, 2 h, 88%. 
The subsequent characterisation revealed several interesting properties, 
such as a high retained brightness upon incorporation into the double-
stranded DNA and a remarkably high two-photon cross-section useful for 
imaging (Paper II). 
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4.1.4 Synthesis of RNA phosphoramidites 
The carefully developed synthetic route that promptly provided adenine 
analogue phosphoramidite building blocks for DNA SPS unfortunately 
did not translate well for the RNA chemistry. We established that the Boc 
protection group previously used was not stable at the N6 position under 
mild Vorbrüggen conditions. The Lewis acidic SnCl4 or trimethylsilyl 
trifluoromethanesulfonate (TMS-OTf) mainly led to a complete Boc 
removal and a complex reaction mixture of various glycosylated 
heterocyclic species. Moreover, screening protecting groups did not 
improve the situation, as benzyl, albeit working for the glycosylation, 
proved too difficult to cleave, and other protection groups were generally 
not stable during the glycosylation. 
Instead, we remodelled the entire synthetic strategy to a more traditional 
and linear one, where the established protocols for glycosylation of 
purines was successfully employed. Several attempts were made to cyclise 
the scaffold using our improved conditions with LiHMDS, but eventually 
only 1,4-diazabicyclo[2.2.2]octane (DABCO) in combination with 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) was adequate as other reactions 
led to depurination, thus lowering the yield significantly.114 
At first, 2-cyano quadracyclic adenine (2CNqA) (Paper III) was 
synthesised as an RNA phosphoramidite. However, following the protocol 
below, with a few minor adjustments, the pA RNA phosphoramidite was 
synthesised accordingly (manuscript in preparation). 
The linear synthesis began with a multi-gram Vorbrüggen N-glycosylation 
of 6-chloro-7-iodo-deazapurine (38) with the benzoyl protected ribose (30, 
Scheme 23) with a modest yield (60%). 
 
Scheme 23. Vorbrüggen reaction employed to yield 73. Reagents and reaction 
conditions: i) N,O-bis(trimethylsilyl)acetamide (1.1 eq.), MeCN, rt, 20 min. ii) 
ribose (1.3 eq.), TMS-OTf (1.1 eq.), 80 °C, 2 h, 60%. 
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The borylation of 73 using the previously described method in Papers I–
II, furnished 74 in good yield (76%, Scheme 24). The required 3-amino-
4-iodobenonitrile (75) was Boc protected using sodium 
bis(trimethylsilyl)amide (NaHMDS) as a base, followed by the addition 
of a diluted Boc anhydride solution in THF at -78 °C to avoid forming 
doubly protected material, thus yielding 76. Compounds 74 and 76 were 
coupled via the Suzuki-Miyaura cross-coupling reaction previously 
described; however, it was performed under strictly anhydrous conditions 
to mitigate Boc deprotection as observed from using a mixture of 
acetonitrile and water, in a good yield of 77 (83%). 
 
Scheme 24. Synthesis of the advanced intermediate 77 towards a 2CNqA RNA 
phosphoramidite. Reagents and reaction conditions: (a) Pd(PPh3)4 (2 mol%), 
HBPin (1.5 eq.), Et3N (10 eq.), THF, 80 °C, 36 h, 76%. (b) Boc2O (1.1 eq.), 
NaHMDS (2 eq.), THF, -78 °C, 1 h, 81%. (c) Compound 76 (1 eq.), 74 (1.5 eq.) 
PdCl2(PPh3)2 (5 mol%), K2CO3 (2.5 eq.), DME, 80 °C, 55 h, 83%. 
The material was now setup for intramolecular cyclisation according to 
previously reported conditions.114 DABCO was added to transform the C6 
chloride of 77 to a better leaving group and DBU was used as a sterically 
hindered base (Scheme 25). The reaction progressed sluggishly as 
previously reported, however the global deprotection was nearly 
quantitative, thus resulting in a modest yield (46%) over two steps. 
Compound 79 was isolated through precipitation and filtration, thereby 
avoiding the need for flash chromatography. 
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Scheme 25. Synthesis of the unprotected 2CNqA nucleoside. Reagents and 
reaction conditions: (a) DBU, DABCO, DMF, 70 °C, 12 h. (b) NaOMe, MeOH, 
rt, 1 h, 46% over two steps. 
The synthesis of the 2CNqA RNA phosphoramidite was concluded by 
three routine steps (Scheme 26). First, tritylation of 79 using DMTr-Cl in 
pyridine afforded 80 in good yield (80%). Second, the protection of the 2'-
OH in 80 was achieved using TBDMS-Cl, which resulted in a modest 
yield of 81 (67%). Finally, the phosphitylation of 81 with CEP-Cl 
provided the 2CNqA RNA phosphoramidite (82) in excellent yield (96%). 
 
Scheme 26. Completion of the 2CNqA RNA phosphoramidite. (a) DMTr-Cl, 
pyridine, rt, 3 h, 80%. (b) TBDMS-Cl, AgNO3, THF, pyridine, rt, 7 h, 67%. (c) 
CEP-Cl, N,N-diisopropylethylamine, THF, rt, 20 h, 96%. 
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4.2 Oligonucleotide chemistry 
With the FBAs synthesised as the protected phosphoramidites, they were 
ready for incorporation into an oligonucleotide. During our synthesis of 
DNA oligonucleotides 10 nt to 33 nt long, a few issues presented 
themselves (Papers II–III).82 The modified building blocks required a 
mixture of MeCN and toluene for solubilisation prior to synthesis, as 
opposed to the native nucleotides that were dissolved in pure MeCN. The 
total equivalent of phosphoramidite utilised in each coupling reaction was 
25. The DNA oligonucleotides were synthesised according to the standard 
protocols of an Applied Biosystems (ABI) synthesiser using a coupling 
time of 60 s for the native nucleotides and an ample time for the modified 
building blocks (10 mins). The oligonucleotides were synthesised with the 
final trityl protecting group removed, cleaved from the solid support, and 
the nucleobases deprotected with concentrated aqueous ammonia at 55 °C 
for 4 h. The purification was readily achieved by RP-HPLC with a gradient 
of MeCN and triethylammonium bicarbonate (TEAB) usually obtaining a 
purity of >95%. All of the DNA oligonucleotides used in this project were 
synthesised on an ABI 394 automated oligo synthesiser on a 1 µmol scale, 
with solid support pre-loaded cartridges containing the first nucleotide of 
the sequence. 
For the synthesis of the RNA oligonucleotides an OligoPilot ÄKTA 10 
(OP10) was used (Papers III-V). Initially, we attempted to work at a 
similar scale (1 µmole) of synthesis as for the ABI. However, while small 
cartridges (1–3 µmole) can work with the OP10, we could not manage to 
design a protocol that lead to a successful and efficient synthesis. 
Eventually, we opted for a full 32 µmol scale of the desired RNA 
oligonucleotides. A minimum of three equivalents of FBA 
phosphoramidite was necessary for optimum coupling efficiency, leading 
to the expenditure of nearly 100 µmole of FBA phosphoramidite as 
compared to the DNA synthesis in which 25 µmole was adequate. The 
overall efficiency, i.e. amount of FBA phosphoramidite used to obtain a 
certain amount of oligonucleotide, was significantly higher for RNA 
synthesis on the OP10 compared to the DNA synthesis on the ABI. 
Overall, standard parameters were employed for the RNA oligonucleotide 
synthesis. The coupling time of the native nucleotides were set to 5 mins 
and the FBA phosphoramidites to 20 mins. 
The RNA oligonucleotides were initially cleaved from the solid support 
with a prolonged version of the previously used protocol for the DNA 
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oligonucleotides (55 °C, 12 h). We noticed that prolonged exposure of our 
RNA oligonucleotides containing a biotin-C6 handle (Paper V) to 
concentrated ammonia led to the degradation of the handle, which forced 
us to reduce the reaction time to 5 h. Subsequently, the TBDMS protecting 
groups were cleaved with triethylamine trihydroflouride and the RNA 
oligonucleotides was precipitated using n-butanol. 
The purification systems in place did not allow for a straightforward 
purification of 32 µmol of oligonucleotides, in fact, no system was 
prepared for RNA purification. Strict restrictions were placed on buffer 
preparation to avoid contamination by RNase that degrade RNA. A RP-
HPLC system was created from unused components and a new C18 
column with small particle and pore sizes (5 µm, 130 Å) was purchased. 
The price of a large C18 column that could purify a 32 µmole scale RNA 
oligonucleotide synthesis made it  unfeasible. Each RNA oligonucleotide 
was split into 4 or 8 µmole portions and purified individually using a 
gradient comprising MeCN and triethylammonium acetate (TEAA), 
sometimes requiring several re-purifications to obtain the spectroscopical 
quality (>95 %), which was ultimately determined by a LC-TOF-MS 
instrument. 
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4.3 Photophysical properties of the FBAs 
In this section the collected highlights of the photophysical 
characterisation of the FBAs from Papers I–IV is shown. The specialised 
applications of total internal reflection fluorescence microscopy and 2-
photon excitation have been performed by our collaborators (pA, Paper 
II). 
4.3.1 Paper I, qAN1-4 
The synthesis of the qAN1-4 series yielded two bright probes, qAN1 and 
qAN4, with a quantum yield of 0.18 and 0.32 respectively, compared to 
the parent compound qA (0.07). For both qAN1 and qAN4 a red-shift in 
the absorption of ~30nm was observed and a blue-shift in the emission of 
25 and 10nm respectively were observed as compared to qA. However, 
the absorption and emission of qAN1 and qAN4 remained well separated, 
minimising self-quenching. A slight degree of sensitivity to polarity was 
observed for the entire series; the deviating emission spectrum for qAN2 
and qAN3 in water was due to poor solubility (Figure 15). The quantum 
yield varied from 0.13 in methanol to 0.38 in DMSO for qAN1 and 0.12 
in DCM to 0.49 in DMSO for qAN4. The relatively high quantum yield 
and brightness of qAN1 recommended it as a good FBA which we 
characterised fully in 2017 as the first adenine–adenine DNA FRET pair.82 
 
Figure 15. Normalized emission of ethylated qAN1-4 in various solvents. 
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4.3.2 Paper II, pA-qAnitro 
During the small library synthesis of the quadracyclic scaffold, we 
envisioned that an overall increase in molar absorptivity, leading to higher 
overall brightness, may arise from fusing yet another aromatic ring onto 
the qA scaffold (Figure 14). The developed synthetic scheme of qAN1 as 
a DNA phosphoramidite was adopted for pA (Paper II). As a monomer, 
pA had a high brightness (up to 15 200 M-1 cm-1), retained high quantum 
yield across a variety of solvents, 0.64 ≤ ΦF ≤ 0.84, and a clear absorption to 
emission band separation. The incorporation of pA into DNA proved it to be 
an excellent adenine FBA despite its increased size, mainly due to the 
outer ring  positioned in the major groove. From the collected UV-melting 
experiments a slight increase in duplex stability was observed with a Tm 
increase of 1.1 °C on average. The brightness of pA within ssDNA of 2,130 
M-1 cm-1 and dsDNA of 1,370 M-1 cm-1 was on average three-fold higher than 
for qAN1, which was reported to be one of the brightest FBAs in DNA.82  
The pA FBA paired nicely with qAnitro in terms of making a new FRET-pair in 
DNA (Figure 16). For short distances (up to 4 bp separation), the FRETeff is 
nearly 1.0, i.e. when the relative angle between the bases approaches 90°, a 
local FRETeff minima is obtained at 7 bp separation (FRETeff ~0.15). The 
FRETeff increases as the bases becomes aligned (8–10 bp separation). 
Moreover, at longer distances the FRETeff falls close to 0.0 (> 12 bp 
separation). In conclusion, monitoring the changes in which distance or 
orientation has a big impact on FRETeff , such as at 6 bp separation, would be 
highly sensitive. 
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Figure 16. Distance and orientation influencing the FRETeff of the pA-qAnitro 
FRET pair. Blue diamonds represent FRETeff from steady-state spectroscopy and 
red circles FRETeff from lifetime data. The black line is the theoretical, calculated 
FRETeff. 
4.3.3 Paper III, 2CNqA-qAnitro and 2CNqA-tCnitro 
The initial photophysical characterisation of the heterocyclic 2CNqA 
indicated that it would be interesting to study in an oligonucleotide context 
due to its high fluorescent quantum yield.89 We opted to install 2CNqA in 
both the DNA and RNA contexts to better understand how FRET is 
affected by their different duplex structures (Paper III). As an adenine 
mimic, 2CNqA stabilised the duplex DNA on average by 3.6 °C, which is 
significantly higher than pA (1.1 °C on average).  Moreover, in one RNA 
strand, 2CNqA stabilised the duplex RNA by 1.5 °C. The observed 
circular dichroism spectra were largely unchanged compared to the 
unmodified oligonucleotide sequences, and thus, 2CNqA is a non-
perturbing adenine analogue. 
The fluorescent quantum yield of 2CNqA was measured in every possible 
combination of nearest nucleobase neighbour for ssDNA and dsDNA, and 
the quantum yield was 0.26 and 0.28 respectively on average. The values 
in ssDNA ranged from 0.10 to 0.44, while in dsDNA the range was 0.22 
to 0.32. The low dependence on sequence surroundings was observed for 
tC70 and tCO,71 and the quenching effect of neighbouring nucleobases 
when going from ssDNA to dsDNA was observed for qAN1.82 The high 
quantum yield and molar absorptivity (~10,000 M-1 cm-1) in DNA yielded 
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brightness values of 4,400 and 3,200 M-1 cm-1 for ssDNA and dsDNA 
respectively, producing the highest single-photon excitation brightness 
values ever reported for an FBA in an oligonucleotide context. In RNA 
oligonucleotides the 2CNqA FBA showed a somewhat more modest 
quantum yield, on average 0.12. The higher observed quenching in A-form 
RNA than B-form DNA is possibly due the lower distance between the 
nucleobases i.e., higher pi stacking as compared to B-form DNA.  
The FRET pairs studied were 2CNqA-qAnitro in DNA (Figure 17, left) and 
2CNqA-tCnitro in RNA (Figure 17, right). For the FRET experiments, both 
the DNA and the RNA 2CNqA probes performed well due to the high 
overlap integral between donor and acceptor in both instances. The 
observed high overlap integral of 2CNqA-qAnitro in DNA, especially at 
long distances, indicated that the FRET pair can report on longer interbase 
FRET measurements.  
 
Figure 17. Distance and orientation influencing the FRETeff of the 2CNqA-qAnitro 
in DNA (left) and 2CNqA-tCnitro in RNA (right). Black dots represent 
experimentally determined FRETeff. The black line is the theoretical, calculated 
FRETeff. 
4.3.4 Paper IV, tCO-tCnitro 
The ribonucleoside tCO was previously synthesised, incorporated into 
RNA and photophysically characterised.119 In Paper IV, we reported the 
synthesis of the FRET acceptor ribo-tCnitro and the incorporation of the two 
probes in RNA, that constituted the first interbase FRET pair in RNA. Like 
tCO, tCnitro has a stabilising effect on duplex RNA (ΔTm +2.8 °C on 
average). The tCO-tCnitro FRET pair perform well in RNA and the FRETeff 
trend is similar to that of 2CNqA-tCnitro in RNA. 
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In Paper IV, the transition from right–handed A-form RNA to left–
handed Z-form RNA was studied using FRET (Figure 18). The Z-form 
RNA mainly occurs in GC-repeat sequences, providing the tCO-tCnitro 
FRET pair with an excellent opportunity to study the conformational 
change. The structure of the Z-form RNA in the literature was used to 
predict the apparent FRETeff at several virtual donor and acceptor 
separations (Figure 18, top). In general, our measured FRETeff 
corresponded well with the published structures of Z-form RNA, except 
for at 6–8 bp separations. The overall lower measured FRETeff may be 
because the Z-RNA structure differs, as the literature has used 6 bp GC-
repeats, whereas we used 14 bp GC-repeats. The difference between A- 
and Z-form RNA was 25–87% change in FRETeff for seven out of the eight 
studied bp separations (Figure 18, bottom). The results clearly indicated 
that our FRET pair can be used to monitor structural changes in RNA with 
high sensitivity. 
 
Figure 18. Representation of change in FRETeff from A- to Z-form RNA. Top, 
green circles indicates measured FRETeff, the rest are calculated FRETeff values 
based on literature data. Bottom, change in measured FRETeff from A-form 
duplex RNA (black squares) to Z-form duplex RNA (green circles) under high 
salt conditions (8 M NaClO4). 
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4.4 RNA interbase-FRET binding interaction assay 
The foundation of this PhD project entailed synthesising novel adenine 
FBAs (Paper I). This was followed by the incorporation and 
characterisation of our probes in DNA, as well as development of new 
FRET pairs (Paper II). The FRET pairs were then compared between 
DNA and RNA (Paper III) and followed up by investigating structural 
changes in RNA (Paper IV). With three of the four milestones achieved, 
we focused on developing a small molecule binding interaction assay to 
pre-miR constructs using our non-perturbing RNA FRET pairs (Paper V). 
For achieving the last milestone, a proof-of-concept study was designed in 
which we decided to work with pre-miR-21, a known oncomiR.120 
The native pre-miR-21 is a 72 nt long hairpin RNA with several structural 
features, although, most of the structural features are present in 
approximately half of the sequence. Furthermore, from our experience of 
RNA oligonucleotide synthesis combined with the need for several 
modifications, such as FBA replacement or biotin-labelling, we knew that 
the synthesis would be problematic. Instead, we simulated the folding of 
the 72 nt pre-miR-21 sequence and identified exactly where we could 
obtain the most interesting structural features to study using the FRET pair 
(Figure 19, left). This led to the design of a 43 nt, truncated pre-mir-21 
construct, providing the same hairpin type fold as the RNA sequence 
(Figure 19, right). 
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Figure 19. Representation of folded native pre-miR-21 (left) and folded truncated 
pre-miR-21 (right). 
As the assay was intended to utilise FRET pairs, the sequence design and 
placement of the FRET pairs were of utmost importance. For instance, 
FRET in DNA between pA–qAnitro (Paper II) indicated that 6 bp 
separation between donor and acceptor would yield approximately 0.50 
FRETeff, thus creating a sensitive system for changes in the relative 
distance or orientation of the probes. However, for RNA, a 6 bp separation 
would result in a FRETeff of 0.75, whereas a 7 base-pair separation would 
result in FRETeff of 0.50 (0.15 for DNA) (Papers III–IV). A complicating 
factor of FRET pair placement and sequence design is that both the relative 
distance and orientation of the FRET pair are different in a sequence with 
a high structure content as compared to a regular duplex A-form RNA. For 
instance, an abasic site is significantly shorter than a full bp and that any 
contraction in length results in a twist of the helical structure thus 
potentially changing the probe orientation, which affects the FRETeff. 
Nonetheless, we aimed for approximately 7 base-pair separations for the 
placement of our FRET pair in two variations; one with the FRET pair in 
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the loop region (Figure 20, left) and one with the FRET pair in the stem 
region around the A-abasic site and A-C mismatch (Figure 20, right).  
 
Figure 20. Sequence design of FRET labelled truncated pre-miR-21. a) FRET 
pair placed to monitor changes in the hairpin. b) FRET pair placed to monitor 
changes in the stem region. 
Initially, we aimed to test a few known RNA binders to the non-labelled 
truncated pre-miR-21 sequence by ITC. Neomycin has been shown to bind 
RNA, especially pre-miR-21, making it a good starting point for our assay 
development.121 Unfortunately, as the ITC was running, seemingly large 
enthalpic spikes were observed upon the injection of neomycin to the pre-
miR-21 construct. By performing test runs of titrating neomycin to the 
utilised typical phosphate buffer containing ethylenediaminetetraacetic 
acid (EDTA), we found non-specific interactions. These non-specific 
interactions were potentially from a protonation event, due to the observed 
magnitude of the peaks, occurring between the buffer and neomycin. After 
screening several buffer conditions, sodium cacodylate 20mM and NaCl 
80mM at pH 7.2 provided only small changes in the heat of dilution 
enthalpy as neomycin was added. The binding of neomycin to truncated 
pre-miR-21 construct yielded a Kd of 5.2 µM. 
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SPR was then used to validate our ITC data and neomycin tested at seven 
different concentrations to biotinylated truncated pre-miR-21 presented a 
Kd of 2.7 µM. Furthermore, a panel of 11 other aminoglycosides was run 
against both truncated native pre-miR-21 and truncated FRET labelled 
pre-miR-21 (Table 1). The obtained dissociation constants showed no 
major impact of our incorporated FRET pair on the binding affinity of 
aminoglycosides. The Kd of the twelve aminoglycosides ranged from 3 to 
300 µM, which was also the metric used to rank them (SPR Rank, Table 
1). 
We then tested the binding of all 12 aminoglycosides using our FRET pair. 
The FRETeff of the RNA sequences before the addition of aminoglycoside 
was determined and then compared to the FRETeff after addition. In 
general, a reduction in emission was observed, which represented an 
increase in FRETeff. The experiment was performed for both hairpin and 
stem FRET labelled RNA oligonucleotide in two different ways. First, 
aminoglycoside was added to reach 15 µM in the cuvette with 1 µM RNA 
oligonucleotide, resulting in various changes in emission depending on the 
aminoglycoside used, as they vary in binding affinity. Based on the 
dissociation constants from SPR for the 12 aminoglycosides, the required 
amount of aminoglycoside to reach 90% degree of complexation was 
calculated and added. The change in emission after adding 15 µM was 
divided as a fraction of the 90% degree of complexation emission, thus 
normalising the emission change (Δ-FRETeff, Table 1). 
Table 1. List of dissociation constants of twelve aminoglycosides based on SPR 
experiments and change in FRETeff of hairpin- and stem-labelled RNA 
oligonucleotides 
Aminoglycoside SPR, truncated pre-miR-
21 Kd [µM] 
Δ-FRETeff SPR Rank FRET 
Rank 
Neomycin 2.7 0.95 1 1 
Sisomicin 3.9 0.69 2 4 
Tobramycin 8.1 0.81 3 2 
Amikacin 14.8 0.55 4 7 
Gentamicin 16.2 0.64 5 6 
Apramycin 22.4 0.66 6 5 
Netilmicin 28.4 0.73 7 3 
Kanamycin 44.2 0.49 8 8 
Ribostamycin 90.2 0.32 9 9 
Geneticin 101 0.40 10 10 
Streptomycin 134 0.13 11 11 
Hygromycin 291 -0.01 12 12 
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The ranking based on obtained dissociation constant values from SPR 
providing the SPR rank matches well with the ranking based on changes 
in FRETeff, except for amikacin, which for an unknown reason did not 
impact the relative FRETeff as much as expected from its Kd. None of the 
aminoglycosides showed a selective binding to either the stem- or hairpin-
labelled pre-miR-21 construct (Figure 20). Instead, only unspecific 
interactions were observed, supported by SPR data (binding stoichiometry 
of 2 to 4 aminoglycosides per RNA oligonucleotide). 
In summary, a novel RNA small molecule binding interaction assay based 
on interbase FRET between tCO–tCnitro was developed. It was capable of 
distinguishing between good and poor binders of a small library of 
aminoglycosides. This final study fulfils the last milestone and the overall 
goal of the PhD project planned five years ago. 
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5. Concluding remarks 
This thesis describes the development of novel and highly fluorescent 
nucleobase analogues, the construction of phosphoramidite building 
blocks on multi-gram scale for DNA and RNA solid-phase synthesis and 
a new powerful small molecule binding interaction assay to RNA. 
A significant effort was performed early in this project work (Paper I) to 
develop the synthetic tools required for the construction of the FBAs 
described herein. By making an FBA model, significant synthetic effort 
was avoided, which greatly accelerated the process to synthesise 
multicyclic adenine compounds and identify the brightest candidates. 
Small modifications, such as changing a carbon atom to a nitrogen atom, 
had a massive impact on the fluorescence quantum yield in water moving 
from qA (0.07) to qAN1 (0.18), to 2CNqA (0.42) and finally to pA (0.64). 
In Paper II, the synthetic scheme to access multicyclic adenine 
derivatives had been significantly improved upon from the previously 
described synthesis of a qA. The improved synthesis made multi-gram 
synthesis of phosphoramidite building blocks feasible. Once incorporated 
into DNA oligonucleotides, pA proved to maintain a relatively high 
brightness, and functioned well as a FRET donor with the qAnitro as FRET 
acceptor. However, the most interesting properties were studied by our 
collaborators that identified pA as the brightest two-photon excitable FBA 
to date and together with its other properties, pA is a very promising 
molecule for super resolution experiments and imaging applications. 
As my goal was to develop an RNA based molecular binding interaction 
assay, the chemistry to generate RNA phosphoramidite building blocks 
was pursued (Papers III-IV). The synthesis of these compounds proved 
difficult and, unfortunately, we could not adopt our high yielding synthetic 
scheme from the DNA synthesis to accommodate other glycosylation’s 
except using deoxyribose derivatives and thus we had to develop a new 
synthetic pathway for the 2CNqA (Paper III). 
Gratefully, I was able to follow through with the initial PhD project 
description and have constructed a small molecule RNA binding 
interaction assay based on our developed FRET pairs (Paper V). By 
placing FRET pairs in a structurally defined RNA sequence, we could 
accurately report on the relative binding affinities within a series of 
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aminoglycosides. This study marks the beginning for internucleobase 
FRET applications in RNA and holds great promise for future studies. 
In conclusion, our group has done a tremendous research effort in bringing 
new fluorescent nucleobase analogues to the scientific community and the 
applications of them has only just started to emerge. 
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